Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: A pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3)

被引：0
|
作者：
Leonardi, Craig [1 ]
Langley, Richard [2 ]
Blauvelt, Andrew [3 ]
Gordon, Kenneth [4 ]
Shrom, David [5 ]
Kerr, Lisa [5 ]
Stoyko, Ivaylo [5 ]
Reich, Kristian [6 ]
机构：
[1] St Louis Univ, Sch Med, St Louis, MO USA
[2] Dalhousie Univ, Halifax, NS, Canada
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Dermatologikum Hamburg, Hamburg, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
3100
引用
收藏
页码：AB70 / AB70
页数：1
相关论文
共 50 条
  • [1] Rapid onset of efficacy in patients with psoriasis treated with ixekizumab: A pooled analysis of data from two phase 3 randomized clinical trials (UNCOVER-2 and UNCOVER-3)
    Leonardi, C. L.
    Langley, R.
    Blauvelt, A.
    Gordon, K.
    Shrom, D. S.
    Farmer-Kerr, L. N.
    Stoykov, I.
    Ojeh, C.
    Reich, K.
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (03) : E29 - E30
  • [2] Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    Griffiths, Christopher E. M.
    Reich, Kristian
    Lebwohl, Mark
    van de Kerkhof, Peter
    Paul, Carle
    Menter, Alan
    Cameron, Gregory S.
    Erickson, Janelle
    Zhang, Lu
    Secrest, Roberta J.
    Ball, Susan
    Braun, Daniel K.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian J.
    Papp, Kim
    LANCET, 2015, 386 (9993): : 541 - 551
  • [3] Efficacy of ixekizumab therapy: integrated analysis of 3 double-blind, controlled trials UNCOVER-1, UNCOVER-2, UNCOVER-3
    Papp, K.
    Leonardi, C.
    Blauvelt, A.
    Korman, N.
    Ohtsuki, M.
    Reich, K.
    Mallbris, L.
    Ball, S.
    Erickson, J.
    Griffiths, C. E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (09) : S170 - S170
  • [4] Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3
    Leonardi, C. L.
    Blauvelt, A.
    Sofen, H. L.
    Gooderham, M.
    Augustin, M.
    Burge, R.
    Zhu, B.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (09) : 1483 - 1490
  • [5] Impact of ixekizumab treatment on sexual function in moderate-to-severe psoriasis patients: 12 week results from two phase 3 trials UNCOVER-2 and UNCOVER-3
    Guenther, Lyn
    Sofen, Howard
    Cathers, Jennifer
    Poulin, Yves P.
    Lebwohl, Mark
    Bleakman, Alison Potts
    Zhu, Baojin
    Nikai, Enkeleida
    van de Kerkhof, Peter
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB254 - AB254
  • [6] Efficacy and safety of ixekizumab in patients with plaque psoriasis across different degrees of disease severity: results from UNCOVER-2 and UNCOVER-3
    Kemeny, Lajos
    Berggren, Lovisa
    Dossenbach, Martin
    Dutronc, Yves
    Paul, Carle
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (01) : 19 - 26
  • [7] Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)
    Papp, K. A.
    Leonardi, C. L.
    Blauvelt, A.
    Reich, K.
    Korman, N. J.
    Ohtsuki, M.
    Paul, C.
    Ball, S.
    Cameron, G. S.
    Erickson, J.
    Zhang, L.
    Mallbris, L.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (03) : 674 - 681
  • [8] Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)
    Reich, Kristian
    Leonardi, Craig
    Lebwohl, Mark
    Kerdel, Francisco
    Okubo, Yukari
    Romiti, Ricardo
    Goldblum, Orin
    Dennehy, Ellen B.
    Kerr, Lisa
    Sofen, Howard
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2017, 28 (04) : 282 - 287
  • [9] Number needed to treat associated with ixekizumab and etanercept from UNCOVER-2 and UNCOVER-3 Phase III trials in the treatment of moderate-to-severe psoriasis
    Foster, S.
    Zhu, B.
    Burge, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S27 - S27
  • [10] Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
    Menter, A.
    Warren, R. B.
    Langley, R. G.
    Merola, J. F.
    Kerr, L. N.
    Dennehy, E. B.
    Shrom, D.
    Amato, D.
    Okubo, Y.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1686 - 1692
12345